Business Wire

KCI Expands Surgical Portfolio in Europe

Share

KCI, an Acelity Company, today announced the availability of the ABTHERA ADVANCE™ Open Abdomen Dressing in Europe. ABTHERA ADVANCE™ Dressing is the next generation temporary abdominal closure device leveraging the technology and success of ABTHERA™ Open Abdomen Negative Pressure Therapy in bridging abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary.

The ABTHERA ADVANCE™ Dressing demonstrated significant increase in overall tissue, skin and fascia movement, with no change in intra-abdominal pressure in a comparative study in the United States of healthy pigs with an open abdominal wound which were treated with either ABTHERA™ SENSAT.R.A.C.™ OA Dressing or ABTHERA ADVANCE™ Dressing at -125mmHg.1

“Expanding the KCI portfolio in markets outside the United States to offer new solutions for surgeons managing a variety of incision types is a key focus for the Company, as we strive to deliver new ways for patients to heal,” said R. Andrew Eckert, Chief Executive Officer of KCI. “The ABTHERA ADVANCE™ Open Abdomen Dressing has already shown tremendous potential for clinicians managing challenging open abdomens, and we look forward to meeting a need by making this therapy broadly available to European healthcare providers caring for some of their most compromised patients.”

The ABTHERA ADVANCE™ Perforated Foam collapses medially while under negative pressure, actively drawing wound edges together. ABTHERA ADVANCE™ Dressing is designed to manage the open abdomen by:

  • Actively removing fluid and reducing bowel edema
  • Providing medial tension, which helps minimize fascial retraction and loss of domain
  • Providing a separation between the abdominal wall and viscera, protecting abdominal contents
  • Protecting abdominal contents from the external environment
  • Allowing for rapid re-entry with no requirements for sutures for placement

Clinical evidence demonstrates that ABTHERA™ Therapy is associated with improved outcomes, including improved primary fascial closure rates and a reduction in hospital stays when compared to Barker’s vacuum-packing technique (BVPT). In one open label, prospective observational study of 168 patients (111 ABTHERA™ Therapy vs. 57 BVPT), ABTHERA™ Therapy patients had a higher 30-day primary fascial closure rate (69% for ABTHERA™ Therapy vs. 51% for BVPT; p=0.03) and had a reduction in 30-day all-cause mortality compared to patients who received BVPT (14% ABTHERA™ Therapy vs. 30% BVPT; p=0.01).2

“Open abdomens after surgery can create a host of complex problems and complications, including infections and fistula,” said Ron Silverman, M.D., F.A.C.S., Chief Medical Officer, KCI. “Currently, options for effectively managing challenging open abdomens are limited. The ability to address many of the challenges associated with open abdomens with ABTHERA™ Therapy is a vital consideration when treating some of the most critically ill patients.”

About ABTHERA ADVANCE™ Open Abdomen Dressing

The ABTHERA ADVANCE™ Open Abdomen Dressing, when used with a compatible V.A.C.® Therapy Unit, forms a temporary abdominal closure system that helps surgeons take control early when managing a challenging open abdomen and helps achieve primary fascial closure. The intended use of this system is for use in open abdominal wounds, with exposed viscera, including but not limited to abdominal compartment syndrome.

About KCI, an Acelity Company

KCI, an Acelity Company, is a well trusted brand in advanced wound care. We are a leader in negative pressure wound therapy, providing solutions for both wound healing and surgical management. Our product offerings are available in more than 90 countries and deliver value through solutions that speed healing. KCI is a leader in quality, safety and customer experience and is committed to advancing the science of healing. Headquartered in San Antonio, Texas, KCI employs approximately 4,500 people worldwide.

1 Kubiak BD, Albert SP, Gatto, LA, et al. Peritoneal negative pressure therapy prevents multiple organ injury in a chronic porcine sepsis and ischemia / perfusion model. Shock. 2010; 34(5):525-534.

2 Cheatham ML, Demetriades D, Fabian TC, et al. Prospective study examining clinical outcomes associated with a negative pressure wound therapy system and Barker's vacuum packing technique. World J Surg. 2013;37(9):2018-30.

Contact information

Maggie Fairchild
Corporate Communications
Phone: +1-210-330-2666
Email: maggie.fairchild@acelity.com

Caleb Moore
Investor Relations
Phone: +1 (210) 255-6433
Email: caleb.moore@acelity.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead Announces Latest Data in Ongoing HIV Cure Research Program23.7.2019 20:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure. The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “While treatments have improved dramatically, people living with HIV still face a lifetime of therapy and potential complications. That reality drives our ongoing pursuit of a cure for HIV,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses

Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings23.7.2019 15:30:00 CESTPress release

Moody’s Analytics, a global provider of financial intelligence, has won the award for Best Reporting System Provider in the 2019 Waters Rankings. We earned this recognition for our regulatory reporting solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005679/en/ For banks and insurers, staying on top of regulatory changes is critical. Our end-to-end solution handles the entire reporting process, producing 3,000 different regulatory reports covering more than 50 jurisdictions. It automatically delivers all required updates well in advance of the relevant deadlines and makes it easy for clients to review, adjust, audit, and validate their reports. The Moody’s Analytics regulatory surveillance team boasts a wealth of experience in both local and international domains going back decades. They monitor more than 100 supervisor websites to ensure that our clients receive the updates they need in a timely fashion. “Regu

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®23.7.2019 15:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP). In a sub-analysis of the DISCOVER trial, Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly more quickly than Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “Gilead is committed to driving advances in HIV prevention and supporting broader public health initiatives that are designed to reduce HIV infections,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These

Velodyne Lidar Acquires Mapper.ai for ADAS Launch23.7.2019 15:00:00 CESTPress release

Velodyne Lidar, Inc. today announced it has acquired mapping and localization software as well as intellectual property assets from Mapper.ai. Mapper technology will enable Velodyne to accelerate development of Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor. The Velarray is the first solid-state Velodyne lidar sensor that is embeddable and fits behind a windshield, as an integral component for superior, more effective advanced driver assistance systems (ADAS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005257/en/ In addition to ADAS, Velodyne will incorporate Mapper technology into lidar-centric solutions for other emerging applications, including autonomous vehicles, last-mile delivery services, security, smart cities, smart agriculture, robotics, and unmanned aerial vehicles. (Photo: Business Wire) Mapper’s entire leadership and engineering teams will join Velodyne, bol

Wealthy Americans are increasingly willing to invest, new UBS survey finds23.7.2019 14:12:00 CESTPress release

US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey. The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash. Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management, says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing

Andersen Global Expands into Ghana23.7.2019 13:30:00 CESTPress release

Ghana law firm, Sam Okudzeto & Associates, signed a collaboration agreement with Andersen Global, marking Andersen Global’s presence in 13 African countries and over 51 countries worldwide. Located in the capital of Accra, Sam Okudzeto & Associates is one of the largest law firms in Ghana. For the past 48 years, the firm has provided legal advice and guidance in the corporate and commercial areas, including patents and trademarks, mergers and acquisition, tax advisory, corporate banking, international trade and investment, debt recovery, mining and mineral law, industrial and labor, aviation, maritime law, petroleum oil and gas, and intellectual property. Sam Okudzeto & Associates founder and Managing Partner, Sam Okudzeto and Nene Amegatcher, have led the team since the establishment of the firm until Nene Amegatcher was elevated to the Supreme Court. The firm now has four partners and 18 lawyers who have gained international reputation for their keen knowledge and experience with Alt